Home › Drug Reactions › NCT05358535

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Adult patients (age ≥18 years old)
2. Having endoscopic procedure at CUH with anesthesia
3. ASA 3 or above
4. Ejection Fraction test result available

Exclusion Criteria:

1. Known allergies or adverse reactions to study drugs or study drug components or preservatives
2. Patient refusal
3. Clinician refusal
4. Documented cognitive impairments precluding subject ability to consent for themselves unless a surrogate documented legally acceptable decision maker consents for patient participation
5. Prisoner or incarcerated or patients held by law enforcement officials in custody
6. Pregnancy or patient refusal for pregnancy testing or screening (standard UTSW policy and protocol requires pregnancy testing for appropriate patients prior to anesthesia)

About the study

The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).

What is being tested

• Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2) (drug)
• Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7) (drug)

Sponsor: University of Texas Southwestern Medical Center · Participants: 200 · Started: Sep 19, 2022

Contact the study team

• Christopher Choi · Phone: 2146486400
• Kapil Anand · Phone: 2146486400

Official record on ClinicalTrials.gov — NCT05358535

Locations in the U.S.

Conditions

• Drug Reactions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.